LEVULAN KERASTICK: payments to doctors
Payments that named LEVULAN KERASTICK as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.1M
- Providers
- 2,507
- Transactions
- 5,270
- Average per transaction
- $202
The per-transaction average — $202 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,507 providers the average total is $424, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| SUN Pharmaceutical Industries Inc. | $625,730 | 58.8% |
| DUSA Pharmaceuticals, Inc. | $245,760 | 23.1% |
| Sun Pharmaceutical Industries Inc. | $192,327 | 18.1% |